LOS ANGELES, March 18 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on leading Australian biotechnology company Arana Therapeutics, (ASX: AAH; AIM: AAHx). "Cash on hand and royalty revenue alone are equal to roughly US$0.94 in share value. Add to that our US$0.43 probability weighted, DCF value for ART621 and you have a premium of nearly 70% to the current market price. This comes without assigning any value to their current pre-clinical pipeline which we feel has great potential," said Ross Silver, Director of Research for Vista Partners. For more information and to download the free report, please visit the Vista Partners website at http://www.vistap.com.
About Vista Partners:
Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.
About Arana Therapeutics:
Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international
biopharmaceutical company formed through the merger of Peptech and EvoGenix
in August 2007. The company uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer. Arana Therapeutics' innovative engineering
technologies provide the basis for clinical development in the antibody
space, a market which draws on high demand. Arana Therapeutics has the
financial stability and management expertise to accelerate its clinical
programs, and is on track to have at least 3 clinical stage assets within
three years. Arana is listed on the Australian Securities Exchange (ASX)
and the London Stock Exchange (AIM). The pipeline consists of four lead
drug programs: ART621 to treat severe rheumatoid arthritis, psoriasis and
other inflammatory diseases; ART010 to treat osteoporosis and bone cancer;
ART104 to treat solid tumours in colorectal cancer; and ART150 for lung
cancer and melanoma. Additionally, the company has earlier stage products
in development for the treatment of a range of conditions including age
related macular degeneration, psoriasis, colorectal cancer, and leukemia.
Arana has recurring revenues from commercial and development partnerships
with six international companies including GSK, CSL, Centocor (J&J) and
Vista Partners LLC
|SOURCE Vista Partners|
Copyright©2008 PR Newswire.
All rights reserved